Bone Pain and Muscle Weakness in Cancer Patients

Overview

Journal Curr Osteoporos Rep

Publisher Current Science

Specialties Endocrinology
Orthopedics

Date 2017 May 13

PMID 28497213

Citations 14

Authors

Daniel P Milgrom

Neha L Lad

Leonidas G Koniaris

Teresa A Zimmers

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: In this article, we will discuss the current understanding of bone pain and muscle weakness in cancer patients. We will describe the underlying physiology and mechanisms of cancer-induced bone pain (CIBP) and cancer-induced muscle wasting (CIMW), as well as current methods of diagnosis and treatment. We will discuss future therapies and research directions to help patients with these problems.

Recent Findings: There are several pharmacologic therapies that are currently in preclinical and clinical testing that appear to be promising adjuncts to current CIBP and CIMW therapies. Such therapies include resiniferitoxin, which is a targeted inhibitor of noceciptive nerve fibers, and selective androgen receptor modulators, which show promise in increasing lean mass. CIBP and CIMW are significant causes of morbidity in affected patients. Current management is mostly palliative; however, targeted therapies are poised to revolutionize how these problems are treated.

Citing Articles

Meta-analysis of the effect of sophora flavescens on tumor metastasis-induced bone neuropathic pain.

Chang C, Sun D, Zhang Z, He L, Wang Q, Shen Y Front Pharmacol. 2024; 15:1474982.

PMID: 39629083 PMC: 11611551. DOI: 10.3389/fphar.2024.1474982.

Factors Associated with Discharge Destination in Patients with Bone Metastases.

Himematsu H, Shimizu Y, Yuhara T, Hiasa K, Yamazaki M, Hada Y Medicina (Kaunas). 2024; 60(6).

PMID: 38929498 PMC: 11205847. DOI: 10.3390/medicina60060881.

Hypercalcemia in Cancer: Causes, Effects, and Treatment Strategies.

Bartkiewicz P, Kunachowicz D, Filipski M, Stebel A, Ligoda J, Rembialkowska N Cells. 2024; 13(12.

PMID: 38920679 PMC: 11202131. DOI: 10.3390/cells13121051.

Classical cannabinoid receptors as target in cancer-induced bone pain: a systematic review, meta-analysis and bioinformatics validation.

Zeng F, Wade A, Harbert K, Patel S, Holley J, Dehghanpuor C Sci Rep. 2024; 14(1):5782.

PMID: 38461339 PMC: 10924854. DOI: 10.1038/s41598-024-56220-0.

Physical Activity, Alcohol, and Cigarette Use in Urological Cancer Patients over Time since Diagnosis.

Adamczak B, Kuznik Z, Makles S, Wasilewski A, Kosendiak A Healthcare (Basel). 2024; 12(1).

PMID: 38200965 PMC: 10779175. DOI: 10.3390/healthcare12010059.

References

Mercadante S, Arcuri E . Breakthrough pain in cancer patients: pathophysiology and treatment. Cancer Treat Rev. 1999; 24(6):425-32. DOI: 10.1016/s0305-7372(98)90005-6. View

Ohuchi H, Noji S . Fibroblast-growth-factor-induced additional limbs in the study of initiation of limb formation, limb identity, myogenesis, and innervation. Cell Tissue Res. 1999; 296(1):45-56. DOI: 10.1007/s004410051265. View

Schwei M, Honore P, Rogers S, Salak-Johnson J, Finke M, Ramnaraine M . Neurochemical and cellular reorganization of the spinal cord in a murine model of bone cancer pain. J Neurosci. 1999; 19(24):10886-97. PMC: 6784931. View

Gould 3rd H, Gould T, England J, Paul D, Liu Z, Levinson S . A possible role for nerve growth factor in the augmentation of sodium channels in models of chronic pain. Brain Res. 2000; 854(1-2):19-29. DOI: 10.1016/s0006-8993(99)02216-7. View

Clohisy D, Perkins S, Ramnaraine M . Review of cellular mechanisms of tumor osteolysis. Clin Orthop Relat Res. 2000; (373):104-14. DOI: 10.1097/00003086-200004000-00013. View

Boissier S, Ferreras M, Peyruchaud O, Magnetto S, Ebetino F, Colombel M . Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res. 2000; 60(11):2949-54. View

Roodman G . Biology of osteoclast activation in cancer. J Clin Oncol. 2001; 19(15):3562-71. DOI: 10.1200/JCO.2001.19.15.3562. View

Yakar S, Rosen C, Beamer W, Ackert-Bicknell C, Wu Y, Liu J . Circulating levels of IGF-1 directly regulate bone growth and density. J Clin Invest. 2002; 110(6):771-81. PMC: 151128. DOI: 10.1172/JCI15463. View

Obata K, Tsujino H, Yamanaka H, Yi D, Fukuoka T, Hashimoto N . Expression of neurotrophic factors in the dorsal root ganglion in a rat model of lumbar disc herniation. Pain. 2002; 99(1-2):121-32. DOI: 10.1016/s0304-3959(02)00068-4. View

10.

Ji R, Samad T, Jin S, Schmoll R, Woolf C . p38 MAPK activation by NGF in primary sensory neurons after inflammation increases TRPV1 levels and maintains heat hyperalgesia. Neuron. 2002; 36(1):57-68. DOI: 10.1016/s0896-6273(02)00908-x. View

11.

Sabino M, Ghilardi J, Jongen J, Keyser C, Luger N, Mach D . Simultaneous reduction in cancer pain, bone destruction, and tumor growth by selective inhibition of cyclooxygenase-2. Cancer Res. 2002; 62(24):7343-9. View

12.

Kakonen S, Mundy G . Mechanisms of osteolytic bone metastases in breast carcinoma. Cancer. 2003; 97(3 Suppl):834-9. DOI: 10.1002/cncr.11132. View

13.

Syrjala K, Cummings C, Donaldson G . Hypnosis or cognitive behavioral training for the reduction of pain and nausea during cancer treatment: a controlled clinical trial. Pain. 1992; 48(2):137-146. DOI: 10.1016/0304-3959(92)90049-H. View

14.

Mohammad K, Guise T . Mechanisms of osteoblastic metastases: role of endothelin-1. Clin Orthop Relat Res. 2003; (415 Suppl):S67-74. DOI: 10.1097/01.blo.0000093047.96273.4e. View

15.

Honore P, Mantyh P . Bone cancer pain: from mechanism to model to therapy. Pain Med. 2004; 1(4):303-9. DOI: 10.1046/j.1526-4637.2000.00047.x. View

16.

Hiraga T, Williams P, Ueda A, Tamura D, Yoneda T . Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model. Clin Cancer Res. 2004; 10(13):4559-67. DOI: 10.1158/1078-0432.CCR-03-0325. View

17.

Stewart A . Clinical practice. Hypercalcemia associated with cancer. N Engl J Med. 2005; 352(4):373-9. DOI: 10.1056/NEJMcp042806. View

18.

Argiles J, Busquets S, Felipe A, Lopez-Soriano F . Molecular mechanisms involved in muscle wasting in cancer and ageing: cachexia versus sarcopenia. Int J Biochem Cell Biol. 2005; 37(5):1084-104. DOI: 10.1016/j.biocel.2004.10.003. View

19.

Vincenzi B, Santini D, Dicuonzo G, Battistoni F, Gavasci M, La Cesa A . Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients. J Interferon Cytokine Res. 2005; 25(3):144-51. DOI: 10.1089/jir.2005.25.144. View

20.

Kozlow W, Guise T . Breast cancer metastasis to bone: mechanisms of osteolysis and implications for therapy. J Mammary Gland Biol Neoplasia. 2005; 10(2):169-80. DOI: 10.1007/s10911-005-5399-8. View